New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2013
16:18 EDTMYLMylan announces agreement with Biocon for collaboration on insulin products
Mylan (MYL) announced that it has entered into a definitive agreement with Biocon Limited for an exclusive strategic collaboration on the development and commercialization of generic versions of three insulin analog products. Under the terms of this collaboration, Mylan will have the rights to develop and market Biocon's Glargine, the generic version of Sanofi's (SNY) Lantus, Lispro, the generic version of Eli Lilly's (LLY) Humalog, and Aspart, the generic version of Novo Nordisk's (NVO) NovoLog. Mylan and Biocon will share development, capital and certain other costs to bring the products to market. Reported worldwide net sales of Lantus, Humalog and NovoLog for 2012 were approximately $11.5B.
News For MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
10:14 EDTMYLMylan November calls active on takeover speculation
Mylan November 55 & 57.5 calls are active on total call volume of 7,100 contracts (200 puts) on takeover speculation. November call option implied volatility is at 36, December is at 34; compared to its 26-week average of 32 according to Track Data. Active call volume suggests traders taking positions for upside price movement.
09:51 EDTMYLRumor: Mylan strength attributed to takeover speculation
Subscribe for More Information
November 13, 2014
07:38 EDTMYLBloomberg Link to hold a conference
The Year Ahead: 2015 is being held in Washington, D.C. with a pre-conference dinner on November 13 followed by company presentations on November 14,

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use